Nirogyone Therapeutics LLC
Northborough, MA · Biotech · Private
Dual MCT1/4 inhibitor small molecules for triple-negative breast cancer
- Grants
- $5.1M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Inhibitors Of Cellular Transporters For The Treatment Of Tnbc | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibitors Of Cellular Transporters For The Treatment Of Tnbc | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibitors Of Cellular Transporters For The Treatment Of Tnbc | $150,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · TUMOR AND IMMUNO-METABOLISM BASED LACTATE TRANSPORTER INHIBITORs FOR METASTATIC MELANOMA | $292,210 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · TUMOR AND IMMUNO-METABOLISM BASED LACTATE TRANSPORTER INHIBITORs FOR METASTATIC MELANOMA | $292,210 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Development of Tumor and Immuno-Metabolism Based Small Molecule Therapeutics for Refractory Breast Cancer | $1,145,470 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Development of Tumor and Immuno-Metabolism Based Small Molecule Therapeutics for Refractory Breast Cancer | $2,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Tumor and Immuno-Metabolism Based Small Molecule Therapeutics for Refractory Breast Cancer | $854,530 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3135 | PHAGEPRO, INC. | — | — |
| 3136 | HTIC, INC. | — | — |
| 3137 | Sixal Inc | — | — |
| 3138 | Nirogyone Therapeutics LLC | — | — |
| 3139 | SEAK Therapeutics, LLC | — | — |
| 3140 | ALCAMENA STEM CELL THERAPEUTICS, LLC | — | — |
| 3141 | FIBROTHERAPEUTICS INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.